Because PD-L1 expression is found in several canine malignancies, including squamous cell carcinoma, mammary adenocarcinoma, transitional cell carcinoma, and hemangiosarcoma [18, 30–34], ICIs may also be effective for these tumors. This evidence concerns the gene CD274 and angiosarcoma.